Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01632358 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 279
- Enrollment target
NCT01632358: Completed Phase 1 study, sponsored by Novartis Pharmaceuticals.
NCT01632358 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 279 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (365% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01632358, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 279 participants
- Enrollment target
Study Summary
The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
Primary Outcome
Summary statistics on number of patients with total adverse events, serious adverse events and death will be reported.
Interventions
- DRUG Placebo
- DRUG TAP311 capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 279 participants |
| Start Date | 2012-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT01632358 record still lists
NCT01632358 is an interventional study that assigns participants to a tested intervention. The registered 279 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (365% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01632358 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01632358 about?
NCT01632358 is a clinical study titled "Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients". The study will assess the safety, tolerability and pharmacokinetics of TAP311 in patients with dyslipidemia.
What is the current status of trial NCT01632358?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 279 participants. The study started on 2012-06. Estimated completion is 2012-12.
What interventions are being tested in trial NCT01632358?
The interventions under investigation include: Placebo (DRUG), TAP311 capsules (DRUG).
Who is sponsoring clinical trial NCT01632358?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01632358's enrollment target sits among peer trials
279 146th of 2000 higher than 1,855 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04783857 · 279 participants · Phase 4
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
- NCT05407324 · 279 participants · Phase 2
Dazucorilant in Patients With Amyotrophic Lateral Sclerosis
- NCT06299748 · 279 participants
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
- NCT06582784 · 279 participants · NA
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia